By Fineline Cube AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised licensing agreement amending their original 2018 partnership, refocusing efforts on the development of small-molecule tau protein aggregation inhibitors for Alzheimer’s disease (AD) and other neurodegenerative disorders, with emphasis on advancing a lead Tau Morphomer candidate compound and potential backup molecules.
Partnership Amendment Overview
| Item | Detail |
|---|---|
| Original Agreement | 2018 licensing partnership |
| Parties | AC Immune SA (NASDAQ: ACIU) and Eli Lilly (NYSE: LLY) |
| Therapeutic Focus | Small-molecule tau protein aggregation inhibitors |
| Indications | Alzheimer’s disease and other neurodegenerative diseases |
| Lead Asset | Tau Morphomer candidate compound plus backup candidates |
| Upfront Payment | CHF 10 million to AC Immune |
| Next Milestone | First patient dosed in Phase I clinical trial |
Financial Terms & Milestone Structure
The amended agreement maintains AC Immune’s substantial long-term financial upside while providing immediate funding for continued development:
- Immediate Payment: CHF 10 million upfront payment to AC Immune
- Near-Term Milestone: Additional payment upon first patient dosing in Phase I trial
- Total Potential Value: Over CHF 1.7 billion in subsequent development, regulatory, and commercial milestones
- Royalty Structure: Low-double-digit tiered royalties on net sales
- Exclusions: New milestone payments are separate from previously announced amendment milestones
Scientific Rationale & Therapeutic Approach
Tau protein aggregation represents a critical pathological hallmark of Alzheimer’s disease and related tauopathies:
- Target Mechanism: Small-molecule inhibition of tau protein misfolding and aggregation
- Technology Platform: AC Immune’s proprietary Tau Morphomer technology
- Therapeutic Rationale: Addressing tau pathology may provide disease-modifying effects beyond symptomatic treatment
- Development Stage: Preclinical advancement toward Phase I clinical trials
The focus on small-molecule approaches differentiates this program from antibody-based tau therapies, potentially offering advantages in blood-brain barrier penetration, oral bioavailability, and manufacturing scalability.
Strategic Implications
For AC Immune
- Pipeline Validation: Continued Lilly partnership validates Tau Morphomer platform technology
- Financial Stability: Upfront payment supports ongoing operations and pipeline development
- Risk Mitigation: Partnership structure reduces development burden while maintaining significant upside
- Focus Optimization: Enables concentration on core tau and amyloid programs
For Eli Lilly
- Portfolio Diversification: Expands Alzheimer’s pipeline beyond current amyloid-focused approaches
- Scientific Access: Gains access to AC Immune’s specialized tau expertise and proprietary compounds
- Competitive Positioning: Strengthens position in next-generation Alzheimer’s therapeutics
- Risk Management: Balanced investment approach with milestone-based payments
Market Context
The Alzheimer’s disease therapeutics market is experiencing renewed interest following recent regulatory approvals of disease-modifying therapies targeting amyloid pathology. However, significant unmet need remains for treatments addressing tau pathology, which correlates more closely with cognitive decline and disease progression.
AC Immune’s Tau Morphomer approach represents one of several emerging strategies to target tau aggregation, positioning the company at the forefront of next-generation Alzheimer’s research alongside established players like Lilly.
Industry Outlook
This partnership amendment reflects the evolving Alzheimer’s therapeutic landscape, where combination approaches targeting multiple pathological pathways (amyloid + tau) may ultimately prove most effective. The continued collaboration between AC Immune and Lilly demonstrates confidence in tau-targeting strategies despite historical challenges in neurodegenerative drug development.
The substantial milestone structure (CHF 1.7+ billion) indicates Lilly’s commitment to potentially transformative Alzheimer’s therapies, while the small-molecule focus addresses delivery and manufacturability challenges that have limited previous tau-targeting approaches.
Forward-Looking Statements
This brief contains forward-looking statements regarding partnership amendments, clinical development timelines, regulatory approvals, and financial milestones for tau-targeting Alzheimer’s therapies. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and the inherent challenges of neurodegenerative disease drug development.-Fineline Info & Tech